Chemomab Therapeutics Ltd. (CMMB)

NASDAQ: CMMB · IEX Real-Time Price · USD

1.120

-0.030 (-2.61%)

At close: Jul 19, 2024, 4:00 PM

1.110

-0.010 (-0.89%)

Pre-market: Jul 22, 2024, 7:05 AM EDT

Chemomab Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2016
Selling, General & Admin	5.85	7.08	11.56	6.03	1.29	6.25	Upgrade
Research & Development	14.61	18.38	16.98	6.33	4.68	13.3	Upgrade
Other Operating Expenses	0	0	0	0	0	3.35	Upgrade
Operating Expenses	20.46	25.46	28.53	12.37	5.97	22.9	Upgrade
Operating Income	-20.46	-25.46	-28.53	-12.37	-5.97	-22.9	Upgrade
Interest Expense / Income	0	0	0	0	0	4.23	Upgrade
Other Expense / Income	-1.1	-1.24	-0.35	0.11	-0.02	-	Upgrade
Pretax Income	-19.36	-24.22	-28.18	-12.48	-5.95	-27.12	Upgrade
Income Tax	-0.02	0	-0.53	0	0	0	Upgrade
Net Income	-19.34	-24.22	-27.65	-12.48	-5.95	-27.12	Upgrade
Shares Outstanding (Basic)	284	235	228	207	137	9	Upgrade
Shares Outstanding (Diluted)	284	235	228	207	137	9	Upgrade
Shares Change	28.58%	3.26%	9.70%	51.71%	1488.06%	172.65%	Upgrade
EPS (Basic)	-1.56	-2.06	-2.42	-1.20	-0.88	-63.20	Upgrade
EPS (Diluted)	-1.56	-2.06	-2.42	-1.20	-0.88	-63.20	Upgrade
Free Cash Flow	-	-23.61	-20.44	-11.61	-5.28	-16.55	Upgrade
Free Cash Flow Per Share	-	-2.01	-1.80	-1.12	-0.77	-38.44	Upgrade
EBITDA	-	-24.15	-28.12	-12.44	-5.93	-22.62	Upgrade
Depreciation & Amortization	-	0.07	0.06	0.03	0.02	0.28	Upgrade
EBIT	-19.36	-24.22	-28.18	-12.48	-5.95	-22.9	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).